

Analyzing Patterns of Computational Similarity between Kinase Ligands

Jack Ringer

University of New Mexico



Background and Overview

Background

Protein kinases are relevant to a large number of human pathologies, including cancer, immune disorders, and infectious diseases. Protein Kinases have been classified into several different groups (a.k.a. “families”). These classifications are based on sequence similarity, evolutionary conservation, and known functions.

The similarity property principle (SPP), has been enormously influential in the realm of medicinal chemistry [2]. According to the SPP, structurally-similar compounds often exhibit similar properties. Among these properties is biological activity, such that similar compounds often demonstrate similar activity.

This work investigates whether ligands which are active within a particular kinase group are more similar to one another than kinase ligands generally.

Why is this important?

- Relevant to drug discovery research
- If there is a relationship between kinase group and ligand similarity, then it may be informative to look at the ligands of related kinases (i.e., those belonging to the same group)
- There may not be much information on a particular protein target, but related and more well-studied proteins could potentially be informative

Methodology

The set of active ligands and their relationship to specific kinase proteins/groups was determined using data from single protein target binding assays in the ChEMBL database [3].

- Assay/ligand selection based on Pharos [1]
- Remove assays where target was a variant/mutant
- Filtered out PAINS compounds
- Molecular weight of ligand must fall between [200, 900] Da

The criteria above resulted in a dataset with the following properties:

Variable	Value
N. Protein Targets	423
N. Assays	73,487
N. Assay-Ligand Pairs	38,622
N. Unique Ligands	9,995

Ligands are considered active within a Kinase group if they were identified as an active within an assay targeting a protein belonging to the group.

After determining the set of ligands and their group relationship(s), Morgan fingerprints were computed using RDKit. Tanimoto similarity coefficients were then computed between these 2D fingerprints.

Results

Figure 1 provides distributions for the $\binom{N}{2}$ similarity values per group (N = number of ligands), as well as the $\binom{9,995}{2} = 49,945,015$ similarity values calculated for all kinase ligands in the dataset. Table 1 provides additional statistics for each group, as well as results from a Mann-Whitney U test (MWUT).




Figure 1. Comparison of 2D structural similarity distributions by kinase group

Kinase Group	N. Targets	N. Ligands	Group Median	Comparison Median	MWUT p-value
CK1	10	13	0.407	0.129	3.10×10^{-11}
STE	45	425	0.131	0.129	$2.48e \times 10^{-169}$
ATYPICAL	15	357	0.149	0.129	$< 5 \times 10^{-324}$
CAMK	65	597	0.117	0.130	1.0
AGC	59	809	0.116	0.131	1.0
TKL	37	810	0.133	0.129	$< 5 \times 10^{-324}$
CMGC	58	1275	0.122	0.130	1.0
OTHER	56	727	0.127	0.129	1.0
TK	80	5347	0.140	0.121	$< 5 \times 10^{-324}$

Table 1. Table showing comparisons of targets, ligands, and ligand similarity distributions per kinase group. Shown p-values are calculated (with Bonferroni correction) from a MWUT where the alternative hypothesis is that the similarity values within the group are stochastically greater than the distribution of all similarity values.




Figure 2. Plot of enrichment values

Discussion

Limitations

- Not all protein targets are equally well-studied (see Figure 3)
- Only considered Morgan fingerprints + Tanimoto coefficients when measuring “similarity” of ligands
- Methodology does not account for differences in assay conditions
- Data gathered from ChEMBL may not reflect global trends




Figure 3. Scatterplots showing the number of assays (x-axis) and ligands (y-axis) for each protein belonging to each kinase group.

Conclusions

Overall, this study found no clear relationship between kinase group and 2D ligand similarity.

Acknowledgement

Much thanks to my advisor Dr. Vincent Metzger for his guidance and input over the course of this project. I'd also like to thank Dr. Jeremy Yang, Dr. Cristian Bologna, and Dr. Praveen Kumar for their feedback during weekly meetings over the course of the internship. Finally, I'd like to thank the authors of ChEMBL DB [3].

References

- Keith J Kelleher, Timothy K Sheils, Stephen L Mathias, Jeremy J Yang, Vincent T Metzger, Vishal B Siramshetty, Dac-Trung Nguyen, Lars Juhl Jensen, Dušica Vidović, Stephan C Schürer, Jayme Holmes, Karlie R Sharma, Ajay Pillai, Cristian G Bologna, Jeremy S Edwards, Ewy A Mathé, and Tudor I Oprea. Pharos 2023: an integrated resource for the understudied human proteome. *Nucleic Acids Research*, 51(D1), Nov 2022.
- Gerald Maggiora, Martin Vogt, Dagmar Stumpfe, and Jürgen Bajorath. Molecular similarity in medicinal chemistry. *Journal of Medicinal Chemistry*, 57(8):3186–3204, Nov 2013.
- Barbara Zdrazil, Eloy Félix, Fiona Hunter, Emma Manners, James Blackshaw, Sybilla Corbett, Marleen De Veij, Harris Ioannidis, David Méndez, Juan F Mosquera, María Paula Magariños, Nicolas Bosc, Ricardo Arcila, Tefik Kizilören, Anna Gaulton, A. Patricia Bento, Melissa F Adasme, Peter Monecke, Gregory A Landrum, and Andrew R Leach. The chembl database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. *Nucleic Acids Research*, 52(D1), Nov 2023.